Table 1 

Overall observed 3, 5 and 10year survival rates of TCs for both genders in relation to the 4 age cohorts (<20 years, 20–44 years, 45–69 years and >69 years of age) and the 4 histological types (papillary, follicular, medullary and anaplastic carcinomas); n = 310 cases; period 1990–1999. 

1990–1994 



Papillary carcinomas 
Follicular carcinomas 
Medullary carcinomas 
Anaplastic carcinomas 



3 y 
5 y 
10 y 
3 y 
5 y 
10 y 
3 y 
5 y 
10 y 
3 y 
5 y 
10 y 



<20 years 
(0/0) 
(0/0) 
(0/0) 
(0/0) 
(0/0) 
(0/0) 
(0/0) 
(0/0) 
(0/0) 
(0/0) 
(0/0) 
(0/0) 
20–44 y. 
100% (42/42) 
100% (42/42) 
97.6%* (41/42) 
100% (9/9) 
100% (9/9) 
88.9%* (8/9) 
(0/0) 
(0/0) 
(0/0) 
(0/0) 
(0/0) 
(0/0) 
45–69 y. 
91.8%* (45/49) 
89.8%* (44/49) 
87.8%* (43/49) 
90.9%* (10/11) 
90.9%* (10/11) 
81.8%* (9/11) 
66.7%* (2/3) 
66.7%* (2/3) 
66.7%* (2/3) 
(0/0) 
(0/0) 
(0/0) 
>69 years 
66.7%* (2/3) 
33.3%* (1/3) 
0% (0/3) 
57.1%* (4/7) 
42.9%* (3/7) 
42.9%* (3/7) 
100% (1/1) 
100% 1/1) 
100% (1/1) 
0% (0/1) 
0% (0/1) 
0% (0/1) 


1995–1999 



Papillary carcinomas 
Follicular carcinomas 
medullary carcinomas 
Anaplastic carcinomas 



3 y 
5 y 
10 y** 
3 y 
5 y 
10 y** 
3 y 
5 y 
10 y** 
3 y 
5 y 
10 y** 



<20 years 
100% (3/3) 
100% (3/3) 
 
(0/0) 
(0/0) 
 
(0/0) 
(0/0) 
 
(0/0) 
(0/0) 
 
20–44 y. 
100% (65/65) 
100% (65/65) 
 
100% (7/7) 
100% (7/7) 
 
100% (3/3) 
100% (3/3) 
 
(0/0) 
(0/0) 
 
45–69 y. 
98.7%* (76/77) 
98.7%* (76/77) 
 
100% (9/9) 
100% (9/9) 
 
100% (4/4) 
100% (4/4) 
 
0% (0/2) 
0% (0/2) 
 
>69 years 
88.9%* (8/9) 
77.8%* (7/9) 
 
50%* (1/2) 
50%* (1/2) 
 
(0/0) 
(0/0) 
 
0% (0/3) 
0% (0/3) 
 


1990–1999 



Papillary carcinomas 
Follicular carcinomas 
medullary carcinomas 
Anaplastic carcinomas 



3 y 
5 y 
10 y** 
3 y 
5 y 
10 y** 
3 y 
5 y 
10 y** 
3 y 
5 y 
10 y** 



<20 years 
100% (3/3) 
100% (3/3) 
 
(0/0) 
(0/0) 
 
(0/0) 
(0/0) 
 
(0/0) 
(0/0) 
 
20–44 y. 
100% (107/107) 
100% (107/107) 
 
100% (16/16) 
100% (16/16) 
 
100% (3/3) 
100% (3/3) 
 
(0/0) 
(0/0) 
 
45–69 y. 
96.0%* (121/126) 
95.2%* (120/126) 
 
95.0%* (19/20) 
95%* (19/20) 
 
85.7%* (6/7) 
85.7%* (6/7) 
 
0% (0/2) 
0% (0/2) 
 
>69 years 
83.3%* (10/12) 
66.7%* (8/12) 
 
55.6%* (5/9) 
44.4%* (4/9) 
 
100% (1/1) 
100% (1/1) 
 
0% (0/4) 
0% (0/4) 
 


* sample size too small for calculating the 95% confidence interval ** data not yet available 

Scheiden et al. BMC Cancer 2006 6:102 doi:10.1186/147124076102 